Agranulocytosis

Agranulocytosis is a life-threatening hematologic condition defined by a severe reduction in granulocytes - specifically, an absolute neutrophil count (ANC) below 500 cells per microliter. Granulocytes (neutrophils, eosinophils, basophils) form the body's primary defense against bacterial and fungal infections. When their numbers collapse, even commensal organisms can cause overwhelming sepsis within hours.

Drug-induced agranulocytosis is the most common cause encountered in clinical practice. Two mechanisms are involved: immune-mediated destruction of granulocytes (an idiosyncratic reaction unrelated to dose) and direct toxicity to bone marrow precursors. Classic culprits include clozapine (the antipsychotic with the highest risk, requiring mandatory ANC monitoring), antithyroid medicines (methimazole, propylthiouracil), sulfasalazine, ticlopidine, dipyrone, certain chemotherapy agents, and rarely, antibiotics such as trimethoprim-sulfamethoxazole.

Patients typically present with fever, severe sore throat, mouth ulcers, gum inflammation, or rapidly progressing infection - often within the first three months of starting the offending medicine. Because granulocytes are required to mount the visible signs of infection (pus, redness, swelling), classic infectious findings may be muted, making fever the most reliable warning sign. Any patient on a known culprit medicine who develops fever requires immediate complete blood count and prompt evaluation in an emergency setting.

Management requires stopping the suspected medicine, isolating the patient to prevent infection, drawing blood and other cultures, and starting broad-spectrum antibiotics empirically even before culture results return. Granulocyte colony-stimulating factor (G-CSF, filgrastim) may shorten recovery. Mortality, though much improved with modern care, remains 5-10% and rises sharply if treatment is delayed.

A common misconception is that agranulocytosis is the same as 'low white count' from chemotherapy. While both involve neutropenia, medicine-induced idiosyncratic agranulocytosis is a sudden, unpredictable, and severe drop, not a gradual chemotherapy-related decline. Another misconception is that a routine CBC will catch the problem early - in many cases, the drop happens within days, so symptom awareness (fever, sore throat) is more protective than scheduled labs alone.

Prescribers must counsel patients on warning signs, document baseline counts before high-risk medicines, and respect mandatory monitoring programs (such as the clozapine REMS) without exception.

Long-term, patients who recover from agranulocytosis must be permanently labeled with the offending medicine as an allergy or contraindication. Re-exposure can trigger a faster, more severe recurrence. For medicines without therapeutic alternatives (clozapine in treatment-resistant schizophrenia), rechallenge protocols exist but require expert hematology and psychiatry coordination. Bone marrow recovery typically takes one to three weeks after medicine discontinuation, and patients remain at high infection risk during this window. Surveillance with serial CBCs every 24-48 hours guides the duration of isolation and antimicrobial therapy. Mortality has fallen dramatically since the routine use of G-CSF and improved supportive care, but vigilance remains essential.